This lawsuit alleges that Defendants made materially false and misleading statements and omissions about Immunomedics' receipt of and approach to handling a Form 483 from the Food and Drug Administration, which ultimately caused the Company's new drug application to fail.
Block & Leviton is co-lead counsel with Robbins, Geller, Rudman & Dowd LLP in this litigation.
The Court denied Defendants’ Motion to Dismiss on July 31, 2020.
On January 20, 2023, Lead Plaintiffs moved the Court for preliminary approval of a $40 million settlement. Additional information will be provided here. A copy of the relevant preliminary approval papers are available on this page.
Contact our attorneys for a no-cost case evaluation.